34 unknown, 30 completed, 19 recruiting, 6 active not recruiting. 37 Phase 2, 30 Not applicable, 24 Phase 1, 7 Phase 3, 2 Early Phase 1.
Follow Relapse: new trials by email Literature Review of Relapse trials Research Report on Relapse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Quantification of Peripheral Blood iNKTs After Allogeneic Stem Cell Transplantation blood draw - Allogeneic HSCT, Posttransplant Complications | Recruiting | University Hospital Pilsen | 75 | 2026-08-01 | 2026-08-13 | |
| A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy Serplulimab, Second-Line Chemo/Targeted Therapy - Colorectal Cancer, Relapse | Phase 2 | Recruiting | Fudan University | 40 | 2026-05-10 | 2026-05-22 |
| EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases CTC - CTCs, Pancreatic Cancer | Not yet recruiting | Huazhong University of Science and Technology | 20 | 2026-03-01 | 2026-03-04 | |
| Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma Epcoritamab, Loncastuximab Tesirine - Large B-cell Lymphoma, Relapse | Phase 2 | Recruiting | University of Miami | 26 | 2026-01-07 | 2026-10-15 |
| The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia Daratumumab - Aplastic Anemia, Refractory | Phase 1 / Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 37 | 2025-12-10 | 2025-12-17 |
| Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma IA Carboplatin + IA Caelyx, IA Carboplatin + IA Etoposide Phosphate - Glioblastoma Multiforme, Relapse | Phase 2 | Recruiting | Université de Sherbrooke | 120 | 2025-08-01 | 2025-08-07 |
| Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia BITE and DLI - Leukemia, Relapse | Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | 31 | 2025-08-01 | 2025-08-06 |
| CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia RD13-02 - Severe Aplastic Anemia, Relapse | Phase 1 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 15 | 2025-06-19 | 2025-07-24 |
| Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML CVA - Acute Myeloid Leukemia, Relapse | Phase 1 | Recruiting | The First Affiliated Hospital of Xiamen University | 30 | 2025-03-15 | 2025-02-24 |
| Comparative 3-dimensional Superimposition Analysis of Dentition in Horizontal and Vertical Grower During the Retention Phase -A Prospective Clinical Trial'' 3 planes of space - Retention, Relapse | Not applicable | Recruiting | Postgraduate Institute of Dental Sciences Rohtak | 44 | 2025-02-04 | 2026-06-03 |
| Azacitidine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Post-transplant Relapse Prevention. Azacitidine (AZA) - Acute Myeloid Leukemia (AML), Relapse | Phase 2 | Not yet recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 51 | 2025-01-16 | 2025-01-17 |
| ''Comparative Evaluation of Change in Bite Force and Levels of Bone Turnover Markers CTX and BALP in Hyperdivergent and Hypodivergent Cases During Retention Phases-A Prospective Clinical Trial '' Bite force and Gcf - Relapse, Bite Force | Not applicable | Recruiting | Postgraduate Institute of Dental Sciences Rohtak | 40 | 2024-12-25 | 2024-12-10 |
| Motivational Interviews Post Hospitalisation on Maintaining AbstiNence for 1 Year après le Sevrage en Alcool Experimental group : PSH (usual care) with motivational interviewing - Alcohol Use Disorder, Addiction | Not applicable | Recruiting | University Hospital, Montpellier | 104 | 2024-12-18 | 2026-06-18 |
| Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention Azacitidine (AZA) Days 1 - 5, Decitabine (DAC), Venetoclax - T-cell Acute Lymphoblastic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | Phase 2 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 59 | 2024-10-30 | 2025-05-07 |
| Autologous CAR-T Cells Targeting B7-H3 in PDAC iC9-CAR.B7-H3 T cell infusion - Pancreas Cancer, Relapse | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 27 | 2024-07-18 | 2026-06-08 |
| Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells iC9-CAR.B7-H3 T Cell Therapy, cyclophosphamide, fludarabine - Breast Cancer, Relapse | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 42 | 2024-06-27 | 2026-07-28 |
| ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells Chemotherapy, Cell infusion - Hodgkin Lymphoma, Relapse | Phase 1 / Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 31 | 2024-04-25 | 2026-08-06 |
| Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC Cyclophosphamide, Fludarabine, Cell Therapy - Head and Neck Cancer, Relapse | Phase 1 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 33 | 2024-04-05 | 2026-09-16 |
| Allogeneic Immunotherapy of Hematological Malignancies Using Regulatory T-cell Selective Depletion T-reg depleted DLI - Hematological Malignancies, Regulatory T Cell Depletion | Phase 1 / Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 27 | 2024-03-01 | 2024-02-14 |
| Adapted RPM-08 for Substance Use Disorder in Pakistan Adapted Relapse Prevention Module (RPM-08), Treatment as Usual (TAU) - Substance Use Disorder (SUD), Drug Abuse | Not applicable | Completed | Universiti Sains Malaysia | 70 | 2024-01-04 | 2026-04-27 |
Showing 20 of 104. Sign in to see all of them.
Recurrence (104) · Lymphoma (6) · Graft vs Host Disease (5) · Hodgkin Disease (5) · Leukemia, Myeloid, Acute (5) · Multiple Myeloma (5) · Substance-Related Disorders (5) · Alcoholism (4) · Hematologic Neoplasms (4) · Multiple Sclerosis (4) · Pain (4) · Postoperative Complications (4) · Anemia, Aplastic (3) · Depression (3) · Depressive Disorder, Major (3)
Disease Attributes (104) · Pathologic Processes (104) · Pathological Conditions, Signs and Symptoms (104) · Neoplasms (43) · Hemic and Lymphatic Diseases (32) · Neoplasms by Histologic Type (31) · Immune System Diseases (29) · Hematologic Diseases (21) · Immunoproliferative Disorders (19) · Lymphoproliferative Disorders (19) · Mental Disorders (16) · Lymphatic Diseases (15) · Neoplasms by Site (15) · Chemically-Induced Disorders (10) · Behavior (8)
Decitabine (4) · Azacitidine (3) · Cyclophosphamide (3) · Dexamethasone (3) · Blood Specimen Collection (2) · Cell- and Tissue-Based Therapy (2) · Cytarabine (2) · Drug Therapy (2) · Lenalidomide (2) · Primaquine (2) · Psychological Tests (2) · Ribavirin (2) · Rituximab (2) · Transcranial Magnetic Stimulation (2) · carfilzomib (2)
Postgraduate Institute of Dental Sciences Rohtak (6) · Assistance Publique - Hôpitaux de Paris (5) · UNC Lineberger Comprehensive Cancer Center (5) · Institute of Hematology & Blood Diseases Hospital, China (4) · Mehmet Eşref Ulutaş (4) · Central Institute of Mental Health, Mannheim (2) · Chinese PLA General Hospital (2) · Nanfang Hospital, Southern Medical University (2) · Peking University People's Hospital (2) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (2) · University of Athens (2) · Université de Sherbrooke (2) · AHS Cancer Control Alberta (1) · ARCAGY/ GINECO GROUP (1) · Aaron J. Janowsky (1)
China (23) · United States (20) · France (13) · India (7) · Germany (4) · Turkey (Türkiye) (4) · Belgium (3) · Canada (3) · Italy (3) · Denmark (2) · Egypt (2) · Greece (2) · Pakistan (2) · Brazil (1) · Czechia (1)
David Fortin, MD (2) · Dehui Zou, Dr. (2) · Qifa Liu (2) · Adel Nabeeh, MD (1) · Akhil Kumar, MD (1) · Anders Thorell, professor (1) · Andrew J Yee, MD (1) · Anton Hagenbeek, PhD MD (1) · Ashraf Hafez, MD (1) · Ashwin Somasundaram, MD (1) · Attaphol Pawarode, M.D. (1) · Bin Cheng (1) · Bing Xu (1) · Brent Bankhead (1) · Bruno Stankoff, MD Ph.D (1)
PMID 19182205, PMID 19534336, PMID 19760366, PMID 20650872, PMID 22242033, PMID 22284691, PMID 22931705, PMID 23844725, PMID 24026531, PMID 24947313, PMID 26092029, PMID 26299283, PMID 26341722, PMID 27736689, PMID 28338171, PMID 28878892, PMID 28904521, PMID 29113659, PMID 29315015, PMID 29760162, PMID 30698644, PMID 31124471, PMID 31892339, PMID 32164760, PMID 32273476, PMID 32600325, PMID 32873343, PMID 33193314, PMID 33235353, PMID 33934960, PMID 34256456, PMID 34547082, PMID 35286511, PMID 35442430, PMID 35467818, PMID 35964235, PMID 36105799, PMID 36241696, PMID 36372356, PMID 37426102, PMID 37583699, PMID 37722357, PMID 38168815, PMID 38394353, PMID 38573484, PMID 38628105, PMID 38781696, PMID 39325327, PMID 40407912, PMID 40434603
2015 (1), 2019 (1), P50CA058223 (1), P50DA018165 (1), R01CA296807 (1)